Positive News SentimentPositive NewsNASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free ENTA Stock Alerts $13.23 -0.77 (-5.50%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$13.22▼$13.9450-Day Range$12.31▼$17.4652-Week Range$8.08▼$37.75Volume154,128 shsAverage Volume243,800 shsMarket Capitalization$279.95 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Enanta Pharmaceuticals alerts: Email Address Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside46.1% Upside$19.33 Price TargetShort InterestBearish13.94% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment1.61Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.90) to ($4.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 starsMedical Sector231st out of 918 stocksPharmaceutical Preparations Industry94th out of 428 stocks 3.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.94% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 13.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 3.7 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for ENTA on MarketBeat in the last 30 days. MarketBeat Follows8 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.90) to ($4.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesApril 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024March 19, 2024 | money.usnews.comEnanta Pharmaceuticals IncApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereMarch 13, 2024 | seekingalpha.comENTA Enanta Pharmaceuticals, Inc.March 11, 2024 | finance.yahoo.comENTA Oct 2024 20.000 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 22.500 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 10.000 putMarch 6, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereFebruary 12, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportFebruary 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)February 9, 2024 | markets.businessinsider.comMaintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline PotentialFebruary 8, 2024 | finance.yahoo.comQ1 2024 Enanta Pharmaceuticals Inc Earnings CallFebruary 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call TranscriptFebruary 7, 2024 | benzinga.comRecap: Enanta Pharma Q1 EarningsFebruary 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ...February 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue EstimatesFebruary 7, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ETFebruary 6, 2024 | benzinga.comEarnings Preview For Enanta PharmaFebruary 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023January 5, 2024 | markets.businessinsider.comBuy Rating on Enanta Pharmaceuticals Amidst Promising RSV Program Developments and Strategic Expansion into CSU MarketJanuary 5, 2024 | finance.yahoo.comStrength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?January 4, 2024 | finance.yahoo.comEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 16, 2023 | finance.yahoo.comInsider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)December 13, 2023 | finance.yahoo.comWall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should KnowDecember 13, 2023 | finance.yahoo.comWall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should KnowSee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today4/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees145Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$28.00 Low Stock Price Target$11.00 Potential Upside/Downside+46.1%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-187.77% Pretax Margin-184.73% Return on Equity-60.38% Return on Assets-32.29% Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio6.25 Sales & Book Value Annual Sales$79.20 million Price / Sales3.53 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book1.29Miscellaneous Outstanding Shares21,160,000Free Float18,270,000Market Cap$279.95 million OptionableOptionable Beta0.47 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 68)President, CEO & Director Comp: $1.25MMr. Paul J. Mellett Jr. (Age 69)Senior VP of Finance & Administration and CFO Comp: $666.84kDr. Yat Sun Or Ph.D. (Age 72)Senior VP of Research & Development and Chief Scientific Officer Comp: $729.31kMr. Nathaniel S. Gardiner J.D. (Age 70)Senior VP, General Counsel & Secretary Comp: $672.67kMr. Brendan Luu (Age 49)Senior Vice President of Business Development Comp: $622.86kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMs. Tara Lynn Kieffer Ph.D. (Age 46)Senior Vice President of New Product Strategy & Development Comp: $496.85kDr. Scott T. Rottinghaus M.D. (Age 50)Senior VP & Chief Medical Officer Comp: $616.73kMore ExecutivesKey CompetitorsESSA PharmaNASDAQ:EPIXNeoleukin TherapeuticsNASDAQ:NLTXAtea PharmaceuticalsNASDAQ:AVIRVentyx BiosciencesNASDAQ:VTYXMereo BioPharma GroupNASDAQ:MREOView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Sold 2,062 shares on 4/17/2024Ownership: 0.065%Vanguard Group Inc.Bought 133,266 shares on 3/11/2024Ownership: 8.479%Goldman Sachs Group Inc.Sold 105,286 shares on 3/1/2024Ownership: 0.882%Public Employees Retirement System of OhioBought 6,533 shares on 2/16/2024Ownership: 0.153%GSA Capital Partners LLPBought 5,712 shares on 2/16/2024Ownership: 0.136%View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price target for 2024? 6 analysts have issued 1-year price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price targets range from $11.00 to $28.00. On average, they predict the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 46.1% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2024? Enanta Pharmaceuticals' stock was trading at $9.41 at the start of the year. Since then, ENTA shares have increased by 40.6% and is now trading at $13.23. View the best growth stocks for 2024 here. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Wednesday, February, 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.18) by $0.40. The biotechnology company earned $18 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative trailing twelve-month return on equity of 60.38%. What ETFs hold Enanta Pharmaceuticals' stock? ETFs with the largest weight of Enanta Pharmaceuticals (NASDAQ:ENTA) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENTA) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.